Anti-inflammatory drugs and Alzheimer disease

McGeer, P. L.; McGeer, Edith G.; Rogers, Joseph; Sibley, John

doi:10.1016/0140-6736(90)91101-f

Cited by 408 publications

(201 citation statements)

References 5 publications

Supporting

Mentioning

191

Contrasting

Unclassified

Order By: Relevance

“…Activated microglia cells aggregate in the area of amyloid plaques and complement activation, including membrane attack complex, is present around neurofibrillary tangles and dystrophic neurites. 60,61 The release of toxins by these inflammatory cells, including free radicals, leukotrienes and cytokines may further contribute to ongoing neuronal damage. [60][61][62][63] Thus the concept that NSAIDs might slow down or prevent the development of AD has emerged and has inspired several retrospective case-control studies, which have suggested that anti-inflammatory drugs may be protective in AD.…”

Section: Anti-inflammatory Medicationsmentioning

confidence: 99%

“…60,61 The release of toxins by these inflammatory cells, including free radicals, leukotrienes and cytokines may further contribute to ongoing neuronal damage. [60][61][62][63] Thus the concept that NSAIDs might slow down or prevent the development of AD has emerged and has inspired several retrospective case-control studies, which have suggested that anti-inflammatory drugs may be protective in AD. 15,60,[63][64][65] McGeer et al 66 critically reviewed 17 such studies, in which arthritis and use of NSAIDs or steroids were evaluated as risk factors for AD.…”

Section: Anti-inflammatory Medicationsmentioning

confidence: 99%

“…[60][61][62][63] Thus the concept that NSAIDs might slow down or prevent the development of AD has emerged and has inspired several retrospective case-control studies, which have suggested that anti-inflammatory drugs may be protective in AD. 15,60,[63][64][65] McGeer et al 66 critically reviewed 17 such studies, in which arthritis and use of NSAIDs or steroids were evaluated as risk factors for AD. The combined data from the populationbased studies of rheumatoid arthritis revealed an odds ratio of 0.19 for AD (CI: 0.09 -0.41) and for use of NSAIDs, the odds ratios was 0.50 (CI: 0.34 -0.72).…”

Section: Anti-inflammatory Medicationsmentioning

confidence: 99%

See 2 more Smart Citations

Preventing Dementia

Black

Patterson

Feightner

2001

Can. J. Neurol. Sci.

View full text Add to dashboard Cite

Suppl. 1 -S56The concept of primary prevention of dementia is relatively new but will assume increasing importance as dementia prevalence increases in our graying population 1 and as the etiological factors and molecular pathogenetic mechanisms of primary degenerative dementias become better understood. 2Current definitions of dementia require memory impairment and cognitive dysfunction in at least one other domain of sufficient degree to interfere with social functioning.3 In this review we emphasize prevention of dementia in individuals who are cognitively normal but may be at risk for dementia, or who are cognitively impaired but not yet demented. Potential preventative measures include avoidance or control of modifiable risk factors to prevent progression to clinically manifest dementia. Secondary prevention of the degenerative dementias is equivalent to treatment, which is discussed in a companion article in this series. Recent clinical trials have provided evidence for modest symptomatic stabilization with socalled cognitive enhancing agents. If effective retardive therapies or neuroregenerative strategies are developed, in the future it may be possible to delay progression or even partially reverse dementing illness.ABSTRACT: Primary prevention will become increasingly important as dementia prevalence increases and effective retardive therapies are developed. To date, only one randomized controlled trial (involving treatment of systolic hypertension) has demonstrated that the incidence of dementia can be reduced. Physicians should remain alert to possible secondary causes of dementia and correct these whenever possible. Primary and secondary prevention of stroke should reduce dementia related to cerebrovascular disease either directly or as a comorbid factor in Alzheimer's disease (AD). Epidemiological studies have revealed a number of risk factors for AD including genetic mutation, susceptibility genes, positive family history, Down's syndrome, age, sex, years of education, head trauma and neurotoxins. In casecontrol studies non-steroidal anti-inflammatory medication and estrogen replacement therapy appear to decrease the relative risk of developing AD. Further research to develop and test preventative therapies in AD and other dementias should be strongly encouraged.RÉSUMÉ: Prévention de la démence. La prévention primaire va devenir de plus en plus importante à mesure que la prévalence de la démence augmente et que des stratégies efficaces pour en retarder l'apparition sont développées. Pour l'instant, une seule étude randomisée contrôlée (traitement de l'hypertension systolique) a démontré que l'incidence de la démence peut être réduite. Les médecins devraient demeurer vigilants pour détecter la présence causes secondaires de démence et les corriger si possible. La prévention primaire et secondaire de l'accident vasculaire cérébral devrait diminuer l'incidence de la démence reliée à la maladie cérébrovasculaire, soit directement ou comme facteur de comorbidité dans la maladie d'Alzheimer (MA). Des étud...

show abstract

Section: Anti-inflammatory Medicationsmentioning

confidence: 99%

Section: Anti-inflammatory Medicationsmentioning

confidence: 99%

Section: Anti-inflammatory Medicationsmentioning

confidence: 99%

See 1 more Smart Citation

Preventing Dementia

Black

Patterson

Feightner

2001

Can. J. Neurol. Sci.

View full text Add to dashboard Cite

show abstract

“…In a study which reviewed 7490 hospital discharges of elderly patients seeking concomitant diagnoses of RA and AD, it was found that the rate of such occurrence was 0.39%, or six to twelve times lower than would have been predicted (assuming independence of the two diagnoses) by the product of the rates for the individual diseases [17]. As there are growing numbers of AD patients worldwide, there would also be lots of patients of RA would eventually develop AD in later life.…”

Section: Discussionmentioning

confidence: 99%

Donepezil-Induced Onset of Rheumatoid Arthritis: Case Report and Literature Review

2015

J Psychiatry

View full text Add to dashboard Cite

Journal of Psychiatry AbstractDonepezil has been approved for treatment of Alzheimer's disease. The common adverse reactions of donepezil in the treatment of Alzheimer's disease include diarrhea and nausea. However, there are also some other rare clinical cases been reported on administration of donepezil, such as mania and delirious behavior. Here, we report a patient with Alzheimer's disease who was induced the onset of rheumatoid arthritis upon treatment with donepezil.

show abstract

“…The role of neuroinflammation in AD is also apparent from epidemiological, retrospective studies that demonstrated nonsteroidal antiinflammatory drugs to reduce the incidence of AD [33][34][35][36]. Some studies have detected elevated IL-1, IL-6 and TNFα protein in postmortem AD tissue in neuronal and non-neuronal cells [35,37], although there is no change in mRNA levels [38,39].…”

Section: Introductionmentioning

confidence: 99%

Receptors for Interleukins and Tumor Necrosis Factor are Important in Assessing their Roles in CNS Disorders

Szot¹

2017

J Clin Cell Immunol

View full text Add to dashboard Cite

The immune-to-brain communication is still in its infancy but there is a great deal of data to suggest its importance in several central nervous system (CNS) disorders. There are three cytokines, interleukin-1 (IL-1), IL-6 and tumor necrosis factor alpha (TNFα), which have emerged to have a major role in the CNS and in different CNS disorders. The majority of the published work to date has been on examining changes in the levels of these proteins in the CNS with inflammation; but recent work from our laboratory has shown the receptors for these cytokines may also be an important factor in neuroinflammation mediated CNS disorders, because these receptors are solely localized to neurons and are modified when their ligands levels are elevated. For neuroinflammation and the increase in cytokine levels (either by glia or neurons) to influence neurons and consequently affect the development of CNS disorders, the location of these cytokines receptors on neuronal populations may be the key.

show abstract

Anti-inflammatory drugs and Alzheimer disease

Cited by 408 publications

References 5 publications

Preventing Dementia

Preventing Dementia

Donepezil-Induced Onset of Rheumatoid Arthritis: Case Report and Literature Review

Receptors for Interleukins and Tumor Necrosis Factor are Important in Assessing their Roles in CNS Disorders

Contact Info

Product

Resources

About